<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on September 20, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/ct2/show/NCT04502173</url>
  </required_header>
  <id_info>
    <org_study_id>1512602-2</org_study_id>
    <nct_id>NCT04502173</nct_id>
  </id_info>
  <brief_title>Kenya: The Barriers and Facilitators of Scaling up the Ellavi UBT for Postpartum Hemorrhage</brief_title>
  <official_title>Kenya: An Implementation Study on the Barriers and Facilitators of Scaling up the Innovative, Low-cost Ellavi Uterine Balloon Tamponade for Postpartum Hemorrhage</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>PATH</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Department for International Development, United Kingdom</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Nairobi</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>PATH</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this implementation research study is to generate evidence that informs the&#xD;
      successful uptake and adoption of the Ellavi Uterine Balloon Tamponade (UBT) within Kenyan&#xD;
      postpartum hemorrhage (PPH) management programs. The investigators aim to improve the&#xD;
      likelihood that the Ellavi UBT will be integrated into the Kenyan health care system by&#xD;
      obtaining critical feedback from stakeholders and health care providers on the barriers and&#xD;
      facilitators towards its successful adoption and roll out. The research will be done in three&#xD;
      purposively selected University of Nairobi affiliated hospitals in Nairobi county, Kenya.&#xD;
      This study will therefore be exploratory and use a non-experimental design. The study team&#xD;
      will train all obstetric healthcare staff (i.e. obstetricians, midwives, medical officers,&#xD;
      clinical officers) involved in PPH management at the participating healthcare facilities on&#xD;
      use of the Ellavi UBT. The investigators will then gather feedback from the obstetric&#xD;
      healthcare workers (post-training and post-PPH) to understand the barriers to and&#xD;
      facilitators of use in order to evaluate acceptability and feasibility among facilities&#xD;
      providing different levels of care (level 4, level 5 (county), level 6 (tertiary)). This&#xD;
      process will help to generate training and facility level recommendations for improved uptake&#xD;
      and integration into the local maternal care package. Case report forms and semi-quantitative&#xD;
      surveys will be completed by obstetrical care providers to evaluate the primary outcomes of&#xD;
      acceptability and feasibility by measuring: context of use, accuracy of use, perceptions of&#xD;
      the device, user confidence, acceptability, usability, facilitators of use, barriers to use,&#xD;
      use-patterns, and insights into training effectiveness. The secondary outcomes will include&#xD;
      financial data to determine the cost of introducing the Ellavi UBT into the Kenyan PPH&#xD;
      management protocols and the health system. The study will not involve the storage of&#xD;
      biological samples. There is not a direct benefit of the study to the individual&#xD;
      participants. All study participants will sign consent forms.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this implementation research study is to generate evidence that informs the&#xD;
      successful uptake and adoption of the Ellavi UBT within Kenyan MOH PPH management programs&#xD;
      for both public and private sector programs. The investigators aim to generate evidence for&#xD;
      Kenyan stakeholders to use in their decision-making around the use of Ellavi UBT in Kenyan&#xD;
      PPH management programs.&#xD;
&#xD;
      Specific objectives:&#xD;
&#xD;
        1. To determine the adoption, penetration, sustainability and fidelity of implementing the&#xD;
           Ellavi UBT device into PPH care in three health care facilities (2 public facilities, 1&#xD;
           private facility). The investigators will explore the number of health workers and&#xD;
           facilities that receive the PPH and Ellavi UBT training, and percent of health workers&#xD;
           and facilities that adopt the Ellavi UBT device over the 6-month period. The&#xD;
           investigators will also assess factors that influence the adoption, penetration,&#xD;
           sustainability, and fidelity through an operations research survey, and the Ellavi UBT&#xD;
           questionnaire.&#xD;
&#xD;
        2. To determine the appropriateness, acceptability and feasibility of using the Ellavi UBT&#xD;
           in participating health facilities at various levels of care in Nairobi County, the&#xD;
           investigators will explore user comprehension of the Ellavi UBT usage steps, accuracy of&#xD;
           use, perceptions of the device, attitudes towards the device, user confidence,&#xD;
           usability, facilitators of use, barriers to use, use-patterns, and insights into&#xD;
           training effectiveness.&#xD;
&#xD;
             1. Sensitize senior management at each of the three participating facilities,&#xD;
                separately.&#xD;
&#xD;
             2. Conduct two half-day trainings on PPH and Ellavi UBT use at each of the three&#xD;
                participating health facilities separated by: 1) obstetricians, medical and&#xD;
                clinical officers, and 2) midwives.&#xD;
&#xD;
             3. Collect individual initial (post-training) data to assess comprehension of Ellavi&#xD;
                UBT usage steps, perceptions of the device, attitudes towards the device, user&#xD;
                confidence, usability, and insights into training effectiveness.&#xD;
&#xD;
             4. Case Management Form (CMF): Obstetrical care provider will complete a CMF within&#xD;
                24hrs (&lt;24hrs) of managing each PPH event. This will inform the study team of how&#xD;
                decision-making algorithms were applied and accuracy of use.&#xD;
&#xD;
             5. Ellavi UBT Questionnaire: PATH-Kenya study team member will collect individual post&#xD;
                (post-usage) Ellavi UBT use data (&lt;72hrs) from each study participant (obstetrical&#xD;
                care worker) to assess comprehension of Ellavi UBT usage steps, perceptions of the&#xD;
                device, attitudes towards the device, user confidence, usability, facilitators of&#xD;
                use, barriers to use, use-patterns, and insights into training effectiveness.&#xD;
&#xD;
             6. PATH-Kenya study staff will record secondary data from hospital registry books over&#xD;
                the six (6) month duration of this study (March - August 2020) in comparison to the&#xD;
                same six (6) month period in 2019 to examine changes in use of condom catheters,&#xD;
                and Ellavi UBTs.&#xD;
&#xD;
             7. Use the Consolidated Framework for Implementation Research (CFIR) to identify&#xD;
                constructs with the potential to influence the introduction and use of Ellavi UBT.&#xD;
                These constructs will be mapped to questions in the questionnaire, and will be&#xD;
                analyzed to identify their influence on Ellavi UBT use. Constructs that have&#xD;
                influence on the implementation of UBTs (both positively and negatively) will be&#xD;
                disseminated for use in future introduction and scale up of Ellavi UBTs.&#xD;
&#xD;
        3. To determine the cost of introducing the Ellavi UBT into the PPH management protocol and&#xD;
           health system.&#xD;
&#xD;
             1. Estimate the costs of the different obstetrical care provider training components.&#xD;
&#xD;
             2. Estimate the costs for other country-level activities associated with the&#xD;
                introduction of the UBT into the PPH management protocols such as costs for&#xD;
                meetings, advocacy, and communication materials.&#xD;
&#xD;
             3. Qualitatively evaluate the frequency and duration of stock outs of condoms,&#xD;
                catheters, IV fluids (sterilized materials), and sutures.&#xD;
&#xD;
             4. Estimate the costs of staff time spent on assembling a condom catheter UBT and the&#xD;
                costs of supplies used.&#xD;
&#xD;
        4. To disseminate the information in national (KOGS), regional (ECSACOG, AFOG), and&#xD;
           international forums to support information sharing, increased awareness of the role of&#xD;
           UBT for refractory PPH, and adoption of its use.&#xD;
&#xD;
           e. Summarize how the Ellavi UBT can be integrated into curriculums, guidelines, and&#xD;
           hospital systems (e.g. patient-provider friendly materials) by analyzing the key&#xD;
           facilitators and barriers.&#xD;
&#xD;
           f. Host a national level meeting with Kenyan MOH stakeholders and participating&#xD;
           facilities g. Publish and disseminate findings in a peer-reviewed journal h. Present at&#xD;
           international conferences and forums, as funding permits. Show the use of Ellavi UBT&#xD;
           using poster presentations and demonstration sessions at international obstetrics&#xD;
           meetings: FIGO, WHO UBT group, Women Deliver as funding permits.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 1, 2020</start_date>
  <completion_date type="Actual">December 30, 2021</completion_date>
  <primary_completion_date type="Actual">September 30, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Determine the appropriateness, acceptability and feasibility of using the Ellavi UBT via semi-quantitative surveys (quantitative and qualitative measures) with health care providers in Nairobi County.</measure>
    <time_frame>6 months</time_frame>
    <description>Determine feasibility by measuring: 1) user comprehension of the Ellavi UBT usage steps and accuracy of use by evaluating assembly, timing of use, relevance for patient's health status (semi-quantitative measures), 2) facilitators of use and barriers to use (open ended, qualitative questions on facility placement, leadership influence, procurement channels, patient feedback), and 3) insights into training effectiveness (opened ended qualitative questions on preferred methods of training, quality of teaching provided). These outcome measures will be evaluated using both quantitative (multiple choice, likert scale) and qualitative (open ended explanations) responses.&#xD;
Determine acceptability by measuring: perceptions of the device (likert scale), attitudes towards the device (likert scale), user confidence (likert scale), and usability (likert scale).&#xD;
Determine appropriateness by measuring: patterns of use with open ended qualitative questions.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Determine the adoption, penetration, sustainability and fidelity of implementing the Ellavi UBT by examining hospital record books and collecting quantitative data.</measure>
    <time_frame>6 months</time_frame>
    <description>Determine the adoption, penetration, sustainability and fidelity of implementing the Ellavi UBT device into PPH care at 3 health care facilities using semi-quantitative surveys and hospital level record books.&#xD;
Determine penetration: # facilities participating, # health workers trained, % of all health workers trained at each site.&#xD;
Determine adoption: % of facilities that adopted UBT devices, # of trained health workers who used the UBT.&#xD;
Determine sustainability: proportion of facilities and health worker who use UBTs/month, for 6 months; %l of providers that use the UBT correctly for &gt;80% of cases.&#xD;
Determine fidelity: % of all health workers surveyed that used the Ellavi UBT.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Determine the cost of introducing the Ellavi UBT into the PPH management protocol and health system by examining cost data, hospital procurement records, and quantifying labor hours worked.</measure>
    <time_frame>6 months</time_frame>
    <description>Determine the costs of the different training course components by reviewing charges incurred.&#xD;
Determine the costs for country-level activities associated with UBT introduction into the PPH management protocols. This includes costs for meetings, advocacy, and communication materials (e.g. review spreadsheets of costs incurred).&#xD;
Determine the frequency and duration of stock outs of: condoms, catheters, IV fluids (sterilized materials), and sutures by surveying hospital inventory stock.&#xD;
Determine the costs of staff time spent on assembling a condom catheter UBT. Determine the costs of supplied pieces to assemble condoms catheters.</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">200</enrollment>
  <condition>Postpartum Hemorrhage</condition>
  <arm_group>
    <arm_group_label>Training</arm_group_label>
    <description>Study participants trained on how to use the Ellavi intra-uterine balloon tamponade via virtual webinar training. Feedback on training course elements will be obtained for future improvements prior to scaling.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Managing PPH</arm_group_label>
    <description>Study participants who provided refractory PPH care using an Ellavi UBT device will give feedback on the barriers and facilitators to use of the newly registered, low-cost medical device.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Ellavi UBT</intervention_name>
    <description>The study team will train all obstetric healthcare staff (i.e. obstetricians, midwives, medical officers, clinical officers) involved in PPH management at the participating healthcare facilities on use of the Ellavi UBT. This will be done to gather feedback from the healthcare workers (post-training and post-PPH) to understand the barriers to and facilitators of use in order to evaluate acceptability and feasibility among facilities providing different levels of care (level 4, level 5 (county), level 6 (tertiary)).</description>
    <arm_group_label>Managing PPH</arm_group_label>
    <arm_group_label>Training</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Obstetrical care providers who recently participated in a training (before using the Ellavi&#xD;
        UBT device for case management) and/or obstetrical care providers who recently managed a&#xD;
        refractory PPH event. The study participant must work in one of the three participating&#xD;
        health care facilities. The number of interviewees per site will vary depending on the size&#xD;
        of the facility and the number of refractory PPH events.&#xD;
&#xD;
        Eligible participants will be selected based on their participation in a PPH/Ellavi UBT&#xD;
        training session, or their management of a PPH event. The study participants will include&#xD;
        obstetricians, midwives, medical officers and clinical officers currently practicing&#xD;
        medicine at Kenyatta National Hospital, Mbagathi Hospital, or St. Mary's Mission Hospital.&#xD;
        If a facility has only three obstetrical care providers, these people will be re-sampled&#xD;
        for each refractory PPH event to understand their interactions with the Ellavi UBT each&#xD;
        time.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Obstetricians, medical officers, clinical officers, and midwives who recently&#xD;
             participated in a PPH/Ellavi UBT training or managed a refractory PPH case (with or&#xD;
             without the use of an Ellavi UBT (within the past 72 hours) at one of the 3&#xD;
             participating health care facilities.&#xD;
&#xD;
          -  Hospital administrators, supply store managers and/or procurement staff&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        - Obstetricians, medical officers, clinical officers, and midwives working at the facility&#xD;
        who do not agree or consent to participate.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>22 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Megan Parker, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>PATH</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Kenyatta National Hospital</name>
      <address>
        <city>Nairobi</city>
        <country>Kenya</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Kenya</country>
  </location_countries>
  <verification_date>April 2022</verification_date>
  <study_first_submitted>June 11, 2020</study_first_submitted>
  <study_first_submitted_qc>August 3, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 6, 2020</study_first_posted>
  <last_update_submitted>April 20, 2022</last_update_submitted>
  <last_update_submitted_qc>April 20, 2022</last_update_submitted_qc>
  <last_update_posted type="Actual">April 22, 2022</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>PATH</investigator_affiliation>
    <investigator_full_name>Megan Parker</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Postpartum Hemorrhage</mesh_term>
    <mesh_term>Hemorrhage</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>The de-identified data will be shared with the funder in the form of a study report. If data are held on a public database (due to publication requirements), they will not be linked to the study participant and their identity would not be revealed.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>


download date: ClinicalTrials.gov processed this data on September 20, 2023
link text: Link to the current ClinicalTrials.gov record.
url: https://clinicaltrials.gov/ct2/show/NCT04502173
org study id: 1512602-2
nct id: NCT04502173
lead sponsor: 
collaborator: 
collaborator: 
is fda regulated drug: No
is fda regulated device: No
The purpose of this implementation research study is to generate evidence that informs the
      successful uptake and adoption of the Ellavi Uterine Balloon Tamponade (UBT) within Kenyan
      postpartum hemorrhage (PPH) management programs. The investigators aim to improve the
      likelihood that the Ellavi UBT will be integrated into the Kenyan health care system by
      obtaining critical feedback from stakeholders and health care providers on the barriers and
      facilitators towards its successful adoption and roll out. The research will be done in three
      purposively selected University of Nairobi affiliated hospitals in Nairobi county, Kenya.
      This study will therefore be exploratory and use a non-experimental design. The study team
      will train all obstetric healthcare staff (i.e. obstetricians, midwives, medical officers,
      clinical officers) involved in PPH management at the participating healthcare facilities on
      use of the Ellavi UBT. The investigators will then gather feedback from the obstetric
      healthcare workers (post-training and post-PPH) to understand the barriers to and
      facilitators of use in order to evaluate acceptability and feasibility among facilities
      providing different levels of care (level 4, level 5 (county), level 6 (tertiary)). This
      process will help to generate training and facility level recommendations for improved uptake
      and integration into the local maternal care package. Case report forms and semi-quantitative
      surveys will be completed by obstetrical care providers to evaluate the primary outcomes of
      acceptability and feasibility by measuring: context of use, accuracy of use, perceptions of
      the device, user confidence, acceptability, usability, facilitators of use, barriers to use,
      use-patterns, and insights into training effectiveness. The secondary outcomes will include
      financial data to determine the cost of introducing the Ellavi UBT into the Kenyan PPH
      management protocols and the health system. The study will not involve the storage of
      biological samples. There is not a direct benefit of the study to the individual
      participants. All study participants will sign consent forms.
The purpose of this implementation research study is to generate evidence that informs the
      successful uptake and adoption of the Ellavi UBT within Kenyan MOH PPH management programs
      for both public and private sector programs. The investigators aim to generate evidence for
      Kenyan stakeholders to use in their decision-making around the use of Ellavi UBT in Kenyan
      PPH management programs.

      Specific objectives:

        1. To determine the adoption, penetration, sustainability and fidelity of implementing the
           Ellavi UBT device into PPH care in three health care facilities (2 public facilities, 1
           private facility). The investigators will explore the number of health workers and
           facilities that receive the PPH and Ellavi UBT training, and percent of health workers
           and facilities that adopt the Ellavi UBT device over the 6-month period. The
           investigators will also assess factors that influence the adoption, penetration,
           sustainability, and fidelity through an operations research survey, and the Ellavi UBT
           questionnaire.

        2. To determine the appropriateness, acceptability and feasibility of using the Ellavi UBT
           in participating health facilities at various levels of care in Nairobi County, the
           investigators will explore user comprehension of the Ellavi UBT usage steps, accuracy of
           use, perceptions of the device, attitudes towards the device, user confidence,
           usability, facilitators of use, barriers to use, use-patterns, and insights into
           training effectiveness.

             1. Sensitize senior management at each of the three participating facilities,
                separately.

             2. Conduct two half-day trainings on PPH and Ellavi UBT use at each of the three
                participating health facilities separated by: 1) obstetricians, medical and
                clinical officers, and 2) midwives.

             3. Collect individual initial (post-training) data to assess comprehension of Ellavi
                UBT usage steps, perceptions of the device, attitudes towards the device, user
                confidence, usability, and insights into training effectiveness.

             4. Case Management Form (CMF): Obstetrical care provider will complete a CMF within
                24hrs (<24hrs) of managing each PPH event. This will inform the study team of how
                decision-making algorithms were applied and accuracy of use.

             5. Ellavi UBT Questionnaire: PATH-Kenya study team member will collect individual post
                (post-usage) Ellavi UBT use data (<72hrs) from each study participant (obstetrical
                care worker) to assess comprehension of Ellavi UBT usage steps, perceptions of the
                device, attitudes towards the device, user confidence, usability, facilitators of
                use, barriers to use, use-patterns, and insights into training effectiveness.

             6. PATH-Kenya study staff will record secondary data from hospital registry books over
                the six (6) month duration of this study (March - August 2020) in comparison to the
                same six (6) month period in 2019 to examine changes in use of condom catheters,
                and Ellavi UBTs.

             7. Use the Consolidated Framework for Implementation Research (CFIR) to identify
                constructs with the potential to influence the introduction and use of Ellavi UBT.
                These constructs will be mapped to questions in the questionnaire, and will be
                analyzed to identify their influence on Ellavi UBT use. Constructs that have
                influence on the implementation of UBTs (both positively and negatively) will be
                disseminated for use in future introduction and scale up of Ellavi UBTs.

        3. To determine the cost of introducing the Ellavi UBT into the PPH management protocol and
           health system.

             1. Estimate the costs of the different obstetrical care provider training components.

             2. Estimate the costs for other country-level activities associated with the
                introduction of the UBT into the PPH management protocols such as costs for
                meetings, advocacy, and communication materials.

             3. Qualitatively evaluate the frequency and duration of stock outs of condoms,
                catheters, IV fluids (sterilized materials), and sutures.

             4. Estimate the costs of staff time spent on assembling a condom catheter UBT and the
                costs of supplies used.

        4. To disseminate the information in national (KOGS), regional (ECSACOG, AFOG), and
           international forums to support information sharing, increased awareness of the role of
           UBT for refractory PPH, and adoption of its use.

           e. Summarize how the Ellavi UBT can be integrated into curriculums, guidelines, and
           hospital systems (e.g. patient-provider friendly materials) by analyzing the key
           facilitators and barriers.

           f. Host a national level meeting with Kenyan MOH stakeholders and participating
           facilities g. Publish and disseminate findings in a peer-reviewed journal h. Present at
           international conferences and forums, as funding permits. Show the use of Ellavi UBT
           using poster presentations and demonstration sessions at international obstetrics
           meetings: FIGO, WHO UBT group, Women Deliver as funding permits.
observational model: Case-Only
time perspective: Prospective
measure: Determine the appropriateness, acceptability and feasibility of using the Ellavi UBT via semi-quantitative surveys (quantitative and qualitative measures) with health care providers in Nairobi County.
time frame: 6 months
description: Determine feasibility by measuring: 1) user comprehension of the Ellavi UBT usage steps and accuracy of use by evaluating assembly, timing of use, relevance for patient's health status (semi-quantitative measures), 2) facilitators of use and barriers to use (open ended, qualitative questions on facility placement, leadership influence, procurement channels, patient feedback), and 3) insights into training effectiveness (opened ended qualitative questions on preferred methods of training, quality of teaching provided). These outcome measures will be evaluated using both quantitative (multiple choice, likert scale) and qualitative (open ended explanations) responses.
Determine acceptability by measuring: perceptions of the device (likert scale), attitudes towards the device (likert scale), user confidence (likert scale), and usability (likert scale).
Determine appropriateness by measuring: patterns of use with open ended qualitative questions.
measure: Determine the adoption, penetration, sustainability and fidelity of implementing the Ellavi UBT by examining hospital record books and collecting quantitative data.
time frame: 6 months
description: Determine the adoption, penetration, sustainability and fidelity of implementing the Ellavi UBT device into PPH care at 3 health care facilities using semi-quantitative surveys and hospital level record books.
Determine penetration: # facilities participating, # health workers trained, % of all health workers trained at each site.
Determine adoption: % of facilities that adopted UBT devices, # of trained health workers who used the UBT.
Determine sustainability: proportion of facilities and health worker who use UBTs/month, for 6 months; %l of providers that use the UBT correctly for >80% of cases.
Determine fidelity: % of all health workers surveyed that used the Ellavi UBT.
measure: Determine the cost of introducing the Ellavi UBT into the PPH management protocol and health system by examining cost data, hospital procurement records, and quantifying labor hours worked.
time frame: 6 months
description: Determine the costs of the different training course components by reviewing charges incurred.
Determine the costs for country-level activities associated with UBT introduction into the PPH management protocols. This includes costs for meetings, advocacy, and communication materials (e.g. review spreadsheets of costs incurred).
Determine the frequency and duration of stock outs of: condoms, catheters, IV fluids (sterilized materials), and sutures by surveying hospital inventory stock.
Determine the costs of staff time spent on assembling a condom catheter UBT. Determine the costs of supplied pieces to assemble condoms catheters.
arm group label: Training
description: Study participants trained on how to use the Ellavi intra-uterine balloon tamponade via virtual webinar training. Feedback on training course elements will be obtained for future improvements prior to scaling.
arm group label: Managing PPH
description: Study participants who provided refractory PPH care using an Ellavi UBT device will give feedback on the barriers and facilitators to use of the newly registered, low-cost medical device.
intervention type: Device
intervention name: Ellavi UBT
description: The study team will train all obstetric healthcare staff (i.e. obstetricians, midwives, medical officers, clinical officers) involved in PPH management at the participating healthcare facilities on use of the Ellavi UBT. This will be done to gather feedback from the healthcare workers (post-training and post-PPH) to understand the barriers to and facilitators of use in order to evaluate acceptability and feasibility among facilities providing different levels of care (level 4, level 5 (county), level 6 (tertiary)).
arm group label: Managing PPH
arm group label: Training
study pop: 
sampling method: Non-Probability Sample
criteria: 
gender: All
minimum age: 22 Years
maximum age: N/A
last name: Megan Parker, PhD
role: Principal Investigator
affiliation: PATH
facility: 
country: Kenya
responsible party type: Principal Investigator
investigator affiliation: PATH
investigator full name: Megan Parker
investigator title: Principal Investigator
mesh term: Postpartum Hemorrhage
mesh term: Hemorrhage
sharing ipd: No
ipd description: The de-identified data will be shared with the funder in the form of a study report. If data are held on a public database (due to publication requirements), they will not be linked to the study participant and their identity would not be revealed.